| Action | Date | Index | Provider |
|---|---|---|---|
| Join | 2023 | Pharma, Biotech & Life Science | Saudi Exchange |
| Join | 2023 | Tadawul All Share Index (TASI) | Saudi Exchange |
| Jamjoom Pharmaceuticals Factory Co. |
| Jamjoom Pharma HQ, 6558 Al Ouqsour, 3418, Al-Ruwais, Jeddah 23211, Saudi Arabia |
| T : +966 12 6140099 |
| F : +966 12 6140088 |
| www.jamjoompharma.com |
| IR@Jamjoompharma.com |
| Title | Name | As Of |
|---|---|---|
| Chairman: | Mahmoud Jamjoom | 2022 |
| Vice Chairman: | Ahmed Jamjoom | 2022 |
| Board Member: | Waleed Jamjoom | 2025 |
| Noor Sheriff | 2022 | |
| Mohammed Jamjoom | 2022 | |
| Alaa Jamjoom | 2022 | |
| Faris Al Ghannam | 2022 | |
| Javed Mohammad | 2025 | |
| Benjamin Toogood | 2025 |
| Date | Title | File |
|---|---|---|
| 2025 | JAMJOOM PHARMA Quarterly Financials Report Q2 2025 | |
| 2025 | JAMJOOM PHARMA Quarterly Financials Report Q1 2025 | |
| 2025 | JAMJOOM PHARMA Annual Financials Report 2024 | |
| 2024 | JAMJOOM PHARMA Quarterly Financials Report Q3 2024 | |
| 2024 | Jamjoom Pharma reports SAR 305 million net profit in 9M 2024, up 23% YoY | |
| 2024 | JAMJOOM PHARMA Quarterly Financials Report Q2 2024 | |
| 2024 | Jamjoom Pharma reports SAR 210 million net profit in 1H 2024, up 23% YoY | |
| 2024 | JAMJOOM PHARMA Quarterly Financials Report Q1 2024 | |
| 2024 | Jamjoom Pharma reports 22.0% Net Profit growth to SAR 103.0 million in 1Q 2024 | |
| 2024 | JAMJOOM PHARMA Annual Financials Report 2023 | |
| 2024 | Jamjoom Pharma reports 71% net profit growth to SAR292.4 million in 2023 |